Table 1.
Monocytic populations in the central nervous system and CNS metastases
| Population | Markers | Brief description of functions | Role in metastases |
|---|---|---|---|
| Microglia | CD11b, CD68, CD115, CD206, CX3CR1, F4/80, Fcrls++, Iba1+, MerTK, P2ry12++, Siglec-H | In steady state: maintain homeostasis, exhibit a phagocytic activity, have low activity as antigen presenting cells | |
| CD11b, CD45, CD64, CD68, CD115, CD163+/-, CD206, CX3CR1, F4/80, Fcrls+, Iba1++, P2ry12+ | Upon activation: depending on stimuli polarization to an inflammatory of pro-tumorigenic phenotype: morphological changes, phagocytosis and antigen presentation, re-organization of ECM, cytokine and chemokine production | Tumor supporting phenotype degradation of ECM, modulating adaptive immune response, aiding in angiogenesis | |
| CNS border-associated macrophages (BAMs) | CD11b, CD45, CD68, CD115, CD163, CD206, CX3CR1, F4/80 | In steady state: maintain integrity of BBB. Upon pathological activation: modulate BBB integrity and vascular permeability, interact with circulating immune cells, produce reactive oxygen species. |
Tumor supporting phenotype: facilitation of recruitment of cancer cells and immune cells via BBB |
| Infiltrating bone marrow-derived macrophages | CD11b, CD45, CD49D, CD64, CD68, CD115, CD163+/-, CD206, CCR2, F4/80, Ly6C | Infiltrate brain parenchyma mainly after breakdown of BBB; immunoregulatory and immunosuppressive functions; cytoprotective activity. | Tumor supporting phenotype: ECM remodeling, immune suppression, enhancement of angiogenesis. |